Markets
Forward Air After the Merger: Dislocation or Structural Impairment?
Forward Air After the Merger: Dislocation or Structural Impairment?
Top movers
All news
Markets1515 stories
Markets
Equities, indices, macro moves, and market structure from our syndicated feeds.
- Markets
The Replacement Economics Behind Kirby Corporation’s Inland Marine Advantage
The Replacement Economics Behind Kirby Corporation’s Inland Marine Advantage
- Markets
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight
- Markets
Palo Alto Networks: The Sell-off Creates an Opportunity in the AI Era
Palo Alto Networks: The Sell-off Creates an Opportunity in the AI Era
- Markets
UFP Industries: A Through-Cycle Compounder at a Fair Price
UFP Industries: A Through-Cycle Compounder at a Fair Price
MarketsLittelfuse and the Quiet Economics of Electrification
Littelfuse and the Quiet Economics of Electrification
- Markets
What is Your Sell Discipline? Do You Have one?
What is Your Sell Discipline? Do You Have one?
- Markets
Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity
Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity
- Markets
Americold: Cold Storage, Real Value
Americold: Cold Storage, Real Value
- Markets
Cogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026
(RTTNews) - Cogent Biosciences, Inc. (COGT), a clinical-stage biotechnology company, announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for…
MarketsBest Futures Trading Platforms for April 2026
The post Best Futures Trading Platforms for April 2026 by Dan Schmidt appeared first on Benzinga . Visit Benzinga to get more great content like this. Choosing a futures broker is one of the few decisions in trading…
- Markets
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.